This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
CYP2D6 / Cytochrome P450 2D6 · IHC design guide
Design Immunohistochemistry for CYP2D6
Plan CYP2D6 paraffin IHC around high cytoplasmic staining in liver hepatocytes (HPA tissue IHC). This guide covers fixation consistency, controls for DAB background and interpretation in light of its ER and microsome membrane location (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
CYP2D6 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Hepatocyte cytoplasm (HPA tissue IHC); ER and microsome membranes (UniProt) | |
| Staining pattern | High cytoplasmic staining in liver hepatocytes (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6 HIER, heat-mediated (datasheet A00498-1) | |
| Positive control | Liver | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Liver endogenous peroxidase may raise DAB background (standard IHC practice) | |
| Regulation | No specific regulator annotated (UniProt) | |
| Isoform / epitope | 2 isoforms; epitope impact is unspecified (UniProt) |
Section 1
Recommended CYP2D6 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by published CYP2D6 protocols for mouse liver paraffin sections (PMC9759570) and mouse brain frozen sections (PMC3750078).
| Sample | Paraffin-embedded rat intestine tissues; fixative not specified (datasheet A00498-1) |
| Fixation | Image fixative and duration unreported (datasheet A00498-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: Citrate pH 6, 20 min (datasheet A00498-1) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A00498-1) |
| Primary antibody | Rabbit anti-CYP2D6, 0.5-1μg/ml (datasheet A00498-1) |
| Primary incubation | Overnight at 4 °C (datasheet A00498-1) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A00498-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | CYP2D6-positive staining in hepatocytes of liver (HPA tissue IHC: High). HPA tissue profile: High cytoplasmic expression in liver. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated citrate pH 6 retrieval for paraffin sections (datasheet: citrate pH 6 HIER); the liver study used citrate pH 6.1 (PMC9759570).
Section 2
What Is the Expected CYP2D6 Staining Pattern?
CYP2D6 should appear as strong cytoplasmic staining in hepatocytes on liver IHC sections (HPA: High in hepatocytes; high cytoplasmic expression in liver). UniProt places CYP2D6 at the endoplasmic reticulum and microsome membranes, with no annotated transmembrane segment (UniProt P10635: subcellular location and topology). HPA rates the tissue IHC evidence Enhanced, while reporting medium consistency between antibody staining and RNA expression (HPA: tissue IHC reliability).
| Strong cytoplasmic staining in hepatocytes, with tissue structure visible. | This matches the reported liver pattern (HPA: High in hepatocytes; high cytoplasmic expression). Score the proportion and intensity of stained hepatocytes separately from background (general IHC practice). |
| Predominantly nuclear staining, with little hepatocyte cytoplasmic signal. | This conflicts with the reported cytoplasmic IHC pattern (HPA: liver tissue IHC) and membrane-associated location (UniProt P10635: subcellular location). Treat it as suspect until controls and staining conditions are reviewed (general IHC practice). |
| Strong staining in cells other than hepatocytes, especially where HPA reports no detection. | This falls outside the supported positive-cell pattern (HPA: High in hepatocytes). Possible cross-reactivity or endogenous detection activity should be checked with controls; staining alone cannot distinguish them (general IHC practice). |
| Diffuse chromogen over cells and surrounding tissue, without a clear cellular pattern. | This is difficult to score as CYP2D6 because the expected liver result is hepatocyte cytoplasmic staining (HPA: tissue IHC). Review background in the no-primary control and the detection workflow (general IHC practice). |
| No staining in a liver section expected to contain hepatocytes. | This conflicts with the reported high hepatocyte signal (HPA: liver tissue IHC). First check tissue preservation and assay controls, then optimize the IHC conditions; a blank slide alone does not establish absent CYP2D6 (general IHC practice). |
💡Expected CYP2D6 appearanceCall a result positive when hepatocytes show strong cytoplasmic staining (HPA: High in hepatocytes); isolated nuclear, widespread non-hepatocyte, or diffuse tissue staining warrants control review (HPA: liver tissue IHC; general IHC practice).
| Tissue and cell choice | Liver hepatocytes are the supported positive reference (HPA: High in hepatocytes; liver-enriched RNA). Small-intestinal enterocytes have low staining, while the listed negative cell populations were not detected (HPA: tissue IHC). |
| Compartment used for IHC scoring | Score hepatocyte cytoplasm in tissue IHC (HPA: high cytoplasmic expression in liver). UniProt assigns CYP2D6 to endoplasmic reticulum and microsome membranes; that annotation does not specify a resolvable chromogenic pattern (UniProt P10635: subcellular location; general IHC practice). |
| Strength of the tissue evidence | The tissue profile is rated Enhanced but has medium staining–RNA consistency (HPA: tissue IHC reliability). HPA045223 has Enhanced IHC validation (HPA: antibody validation); interpret unexpected sites with controls rather than treating the reference pattern as universal. |
| Isoforms and antibody coverage | UniProt lists two CYP2D6 isoforms (UniProt P10635: isoforms 1 and 2). The supplied records give no epitope or isoform-specific staining result, so they cannot establish whether the antibody detects both isoforms. |
| What should IF/ICC show? | HPA reports a mainly Golgi location in ICC-IF, but rates HPA045223 ICC validation Uncertain (HPA: subcellular ICC-IF; antibody validation). That separate assay result should be assessed on its own terms and does not replace the liver IHC reference pattern (HPA: tissue IHC). |
| Situation | Likely cause | Next action |
|---|---|---|
| Liver hepatocytes are blank. | The result conflicts with the reported high hepatocyte signal (HPA: liver tissue IHC); the cause remains undetermined from this slide. | Check that the section contains preserved hepatocytes and review positive and no-primary controls; then optimize retrieval, antibody dilution, and detection as general IHC variables (general IHC practice). |
| Hepatocyte cytoplasm is weak or patchy. | The observed signal is below the reported high liver pattern (HPA: High in hepatocytes). The supplied sources do not identify a CYP2D6-specific fixation or retrieval sensitivity. | Compare sections and controls processed together; adjust retrieval or dilution systematically and retain the condition that improves cellular contrast (general IHC practice). |
| Nuclei stain more strongly than cytoplasm. | Nuclear predominance disagrees with the reported cytoplasmic tissue pattern (HPA: liver tissue IHC) and the annotated membrane-associated location (UniProt P10635: subcellular location). | Review the no-primary control, chromogen development, and antibody concentration before counting nuclear staining as target signal (general IHC practice). |
| Cells in an HPA negative reference tissue stain strongly. | This differs from the stated result for the specific tissue and cell population (HPA: tissue IHC negative entries); it does not by itself identify cross-reactivity. | Confirm the stained cell type and compare liver positive and no-primary controls in the same run; investigate persistent cell-specific signal before reporting CYP2D6 (general IHC practice). |
| Chromogen covers broad tissue areas or control sections. | Diffuse deposition obscures the expected hepatocyte cytoplasmic pattern (HPA: liver tissue IHC). Endogenous detection activity or assay background are possibilities (general IHC practice). | Inspect the no-primary control; review blocking, washes, and detection reagent timing, then repeat with the background source addressed (general IHC practice). |
| IF/ICC appears Golgi-like while liver IHC is cytoplasmic. | HPA reports Golgi localization for ICC-IF and cytoplasmic staining for liver IHC; HPA045223 ICC validation is Uncertain (HPA: subcellular ICC-IF; tissue IHC; antibody validation). | Interpret each assay against its own HPA reference and validation status. Use the liver hepatocyte pattern for IHC scoring; assess IF/ICC evidence separately (HPA: tissue IHC; subcellular ICC-IF). |
Experiment evidence
IHC & IF images showing CYP2D6 staining
A00498-1 · IHCIHC analysis of Cytochrome P450 2D6 using anti-Cytochrome P450 2D6 antibody (A00498-1). Cytochrome P450 2D6 was detected in paraffin-embedde
A00498-1 · IHCIHC analysis of Cytochrome P450 2D6 using anti-Cytochrome P450 2D6 antibody (A00498-1). Cytochrome P450 2D6 was detected in paraffin-embedde
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000100197-CYP2D6/tissue/cerebral+cortex#imid_21037323
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000100197-CYP2D6/tissue/colon#imid_21039625
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000100197-CYP2D6/tissue/liver#imid_21039618
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000100197-CYP2D6/tissue/kidney#imid_21039627
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA045223; green = CYP2D6, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA045223; green = CYP2D6, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for CYP2D6 IHC & IF
🧪Run liver first: hepatocytes should show the strongest CYP2D6 staining (HPA: High in liver hepatocytes). Use adipose tissue as the negative tissue (HPA: Not detected in adipocytes); on the liver slide, non-hepatocyte cells should be assessed for background-level staining, although their CYP2D6 status is not specified by the supplied HPA rows.
Positive control tissue: Liver (Hepatocytes, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show CYP2D6 in A-431, U-251MG, U2OS, with annotated localisation: Golgi apparatus (approved) (HPA subcellular).
Technical controls: Include a no-primary (secondary-only) slide, a concentration-matched rabbit isotype control (caption: rabbit primary), and CYP2D6-knockout tissue if available as a biological negative (standard IHC practice). Block endogenous peroxidase and check for endogenous biotin signal in liver sections before interpreting the chromogen (caption: SABC/DAB detection; standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A00498-1 paraffin-section caption does not state the fixative (caption: fixative unreported). The caption reports citrate retrieval at pH 6 for 20 minutes in rat intestine; whether that retrieval is required or optimal for liver is unreported (caption: rat intestine IHC). Frozen sections or IF cannot be judged easier from the supplied evidence; liver peroxidase activity and endogenous biotin can complicate SABC/DAB interpretation (caption: SABC/DAB detection; standard IHC practice).
HPA tissue IHC evidence for CYP2D6
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Liver | Hepatocytes | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | Endocrine cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced CYP2D6 IHC Tips
Troubleshoot CYP2D6 staining in paraffin sections with chromogenic IHC, using the selected antibody’s tissue image and independent expression evidence as reference points.
Which retrieval conditions should I start with for CYP2D6 in paraffin sections?
Start with heat-mediated citrate buffer at pH 6 for 20 minutes (datasheet A00498-1). Apply the same heating and cooling schedule across comparison sections, then inspect hepatocyte cytoplasmic staining alongside tissue morphology; hepatocytes show high CYP2D6 expression in the reference tissue profile (HPA tissue IHC; standard IHC practice). If signal is weak, adjust heating duration on matched sections before testing another retrieval buffer, while keeping antibody concentration and detection constant (standard IHC practice). Record whether stronger staining also raises diffuse background or damages tissue, since either change can make an apparent retrieval improvement misleading (standard IHC practice).
Could fixation explain weak or uneven CYP2D6 staining?
The selected paraffin-section caption does not state a fixative, so target-specific CYP2D6 sensitivity to fixation is unknown (caption A00498-1). Record the actual fixative and fixation duration for each specimen, and compare sections processed under matched conditions before attributing a weak result to the antibody (standard IHC practice). Repeat the stated citrate pH 6, 20-minute retrieval on a reference section when investigating variable staining (datasheet A00498-1). Inspect morphology and section edges alongside signal intensity: uneven penetration or processing can produce regional staining differences, but those observations alone cannot establish a CYP2D6-specific fixation effect (standard IHC practice).
What staining pattern should I expect for CYP2D6?
Expect predominantly intracellular cytoplasmic staining in hepatocytes on tissue IHC; the reference profile reports high expression there (HPA tissue IHC). CYP2D6 is associated with endoplasmic reticulum and microsome membranes, although its record annotates no transmembrane segment (UniProt P10635 subcellular location and topology). Interpret a cytoplasmic chromogenic signal at tissue-section resolution without claiming that DAB identifies individual organelles (standard IHC practice). An approved subcellular ICC/IF annotation instead places CYP2D6 mainly at the Golgi apparatus, so record the observed pattern and avoid treating either organelle assignment as established by chromogenic tissue staining alone (HPA subcellular; standard IHC practice).
Can this antibody distinguish CYP2D6 isoforms in tissue?
The protein record lists 2 isoforms, but the supplied tissue-IHC caption gives no antibody epitope or isoform-specific validation (UniProt P10635 isoforms; caption A00498-1). Check the catalog antibody’s epitope documentation before claiming that staining represents one isoform; an image obtained with 1 μg/mL antibody establishes staining conditions, not isoform discrimination (caption A00498-1; standard IHC interpretation). The record annotates no glycosylation sites or modified residues, which does not identify the antibody’s recognized sequence (UniProt P10635 PTMs; standard IHC interpretation). Report the result as CYP2D6 immunoreactivity unless separate epitope mapping or isoform-selective controls support a narrower conclusion (standard IHC practice).
How should I adapt CYP2D6 detection for multiplex IF?
Treat IF as a separately optimized application; the selected antibody caption documents chromogenic staining of a paraffin section (caption A00498-1). Pair CYP2D6 with a validated hepatocyte marker when examining liver, because hepatocytes show high expression in the tissue reference profile (HPA tissue IHC; standard IF practice). Choose spectrally separated fluorophores after checking tissue autofluorescence and single-color controls, and place a weaker signal in the cleaner detection channel (standard IF practice). Because CYP2D6 is associated with endoplasmic reticulum and microsome membranes, optimize permeabilisation to expose the antibody’s epitope on its accessible membrane side; the epitope side is unspecified here (UniProt P10635 subcellular location; standard IF practice).
How can I reduce diffuse DAB background without losing CYP2D6 signal?
Use the selected caption’s 10% goat-serum block, 1 μg/mL primary antibody overnight at 4°C, and biotinylated secondary with DAB as a documented starting workflow (caption A00498-1). Include a no-primary section to assess secondary and detection background, and block endogenous peroxidase before DAB development as a general chromogenic IHC step (standard IHC practice). Because the documented detection uses a biotin-based complex, consider a biotin-related background control when staining appears widespread (caption A00498-1; standard IHC practice). Compare any reduction in background with retained hepatocyte cytoplasmic signal, rather than judging cleaner slides by overall color alone (HPA tissue IHC; standard IHC practice).
What should I measure when comparing CYP2D6 IHC across samples? ⚠ ANSWER MARKED FOR VERIFICATION
Define the analysis region and cell population before scoring; the reference tissue profile identifies hepatocytes as strongly positive and small-intestinal enterocytes as low (HPA tissue IHC). For comparable liver sections, score hepatocyte staining with an H-score based on percentage at each intensity, and report the percentage of positive hepatocytes separately (standard IHC practice). Normalize counts to the number of evaluable hepatocytes or measured tissue area, and use cells per mm² only when reporting positive-cell density (standard IHC practice). Keep retrieval, imaging, DAB development and positivity thresholds consistent across batches, while excluding folds, edges and necrotic regions from measurements (standard IHC practice).
How do I distinguish credible CYP2D6 staining from artefact?
A credible liver result shows hepatocyte cytoplasmic staining in intact tissue, consistent with the reference expression profile and CYP2D6’s intracellular membrane association (HPA tissue IHC; UniProt P10635 subcellular location). Be cautious with exclusively nuclear or extracellular DAB, staining confined to damaged edges, or signal concentrated in necrotic regions; assess these against morphology and a no-primary control (standard IHC practice). Check peroxidase blocking if widespread DAB persists without primary antibody, because endogenous enzyme activity can mimic a positive chromogenic reaction (standard IHC practice). Treat isolated Golgi-like staining cautiously: that organelle assignment comes from ICC/IF data, whereas chromogenic tissue sections provide limited organelle resolution (HPA subcellular; standard IHC practice).
Boster reagents
Best CYP2D6 / Cytochrome P450 2D6 IHC Antibodies
A00498-1 has IHC images from paraffin sections of rat intestine, mouse liver and intestine, and human liver cancer (IHC captions); M00498 lists human IF/ICC, with no image supplied (catalog).
Real IHC data
Anti-Cytochrome P450 2D6/CYP2D6 Antibody ®
Cat # A00498-1
A00498-1 is listed for human, mouse and rat IHC, with illustrated paraffin sections from rat intestine, mouse liver and intestine, and human liver cancer (catalog applications/reactivity; A00498-1 IHC captions). M00498 is listed for human IHC and IF/ICC, but has no IHC or IF image in the payload (catalog applications/reactivity; image alts).
Which to pick: For tissue IHC, choose A00498-1: its own paraffin-section captions document citrate retrieval at pH 6 for 20 minutes and primary antibody at 1 μg/ml overnight at 4°C; the fixative is unreported (A00498-1 IHC captions). For IF/ICC, M00498 is the listed option, a rabbit monoclonal for human samples, though no IF image is supplied (M00498 catalog applications/reactivity/clone; image alts). For cross-species IHC, choose A00498-1 because it lists human, mouse and rat reactivity and has IHC images for all three (A00498-1 catalog reactivity; IHC captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P10635 (CP2D6_HUMAN, Cytochrome P450 2D6).
- Human Protein Atlas. CYP2D6 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. CYP2D6 subcellular location (ICC-IF): Mainly localized to the Golgi apparatus..
- Human Protein Atlas. CYP2D6 antibody validation summary (1 antibodies).
- Hepatic progenitor cells of biliary origin with liver repopulation capacity. Nature cell biology 2015 — PMC4612439.
- Generation of hepatic spheroids using human hepatocyte-derived liver progenitor-like cells for hepatotoxicity screening. Theranostics 2019 — PMC6771233.
- Periportal steatosis in mice affects distinct parameters of pericentral drug metabolism. Scientific reports 2022 — PMC9759570.
- Potential role of CYP2D6 in the central nervous system. Xenobiotica; the fate of foreign compounds in biological systems 2013 — PMC3750078.
- PubMed PMID:3410476 — UniProt-cited evidence.
- PubMed PMID:3123997 — UniProt-cited evidence.
- PubMed PMID:2574001 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for CYP2D6 (Cytochrome P450 2D6). Expected localisation Hepatocyte cytoplasm (HPA tissue IHC); ER and microsome membranes (UniProt). Antigen retrieval: Citrate pH 6 HIER, heat-mediated (datasheet A00498-1). Validated IHC antibody: A00498-1 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Liver (Hepatocytes); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded rat intestine tissues; fixative not specified (datasheet A00498-1); 2. Fixation: Image fixative and duration unreported (datasheet A00498-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: Citrate pH 6 , 20 min (datasheet A00498-1); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A00498-1); 8. Primary antibody: Rabbit anti-CYP2D6, 0.5-1μg/ml (datasheet A00498-1); 9. Primary incubation: Overnight at 4 °C (datasheet A00498-1). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Liver endogenous peroxidase may raise DAB background (standard IHC practice); Isoform / epitope: 2 isoforms; epitope impact is unspecified (UniProt); Regulation: No specific regulator annotated (UniProt). Evidence: UniProt P10635, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the Golgi apparatus., Datasheet A00498-1, PMC9759570, PMC3750078. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/CYP2D6/immunohistochemistry-ihc-guide.